Zivo Bioscience Stock Price, News & Analysis

ZIVO Bioscience, Inc. (ZIVO) is a biotech and agtech research and development company focused on therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures. The company describes itself as a research and development business with an intellectual property portfolio that includes proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health.

ZIVO’s work centers on developing non-antibiotic, algae-derived compounds intended to support immune function and address disease challenges in livestock and potentially in human nutrition. According to multiple company communications, its proprietary active ingredients are being investigated as feed ingredients and biologics that may modulate immune responses and help manage parasitic and viral diseases in poultry, particularly coccidiosis and Low Pathogenicity Avian Influenza (LPAI). These activities position ZIVO within the biological product manufacturing and animal health research landscape, with a focus on agriculture and food production.

Core focus: algal-derived actives for animal and human health

Across its disclosures and news releases, ZIVO emphasizes an intellectual property portfolio built around:

• Proprietary algal and bacterial strains
• Biologically active molecules and complexes derived from these strains
• Production and cultivation techniques
• Patented or patent-pending inventions for human and animal health applications

In animal health, ZIVO reports that its product candidates are designed as non-antibiotic, immune-modulating interventions. For poultry, its feed product candidate is described as intended to boost immune response so that birds can better combat coccidiosis and reduce the negative effects of the disease without relying on antibiotics. Studies cited by the company indicate that these actives are being evaluated both as standalone interventions and as complements to existing tools such as ionophore-based treatments and vaccines.

Poultry health: coccidiosis and avian influenza research

A recurring theme in ZIVO’s communications is the development of product candidates targeting coccidiosis in broiler chickens. The company has reported results from 42-day challenge and confirmatory studies conducted under conditions intended to reflect commercial poultry production. In these studies, broiler chickens infected with coccidiosis and treated with ZIVO’s product, alone or in combination with ionophores or vaccination, showed statistically significant improvements in measures such as intestinal lesion scores and feed conversion ratio compared with infected, untreated controls. In some cases, performance metrics for treated birds were reported as comparable to healthy, uninfected controls.

ZIVO also highlights research collaborations focused on Low Pathogenicity Avian Influenza (LPAI). Studies conducted with the University of Delaware evaluated whether ZIVO’s proprietary active ingredients could reduce viral shedding and slow disease transmission among poultry. Company reports describe reductions in viral titers in treated birds compared with untreated controls, and delays in transmission when healthy birds were housed with infected birds. Follow-on work has explored different formulations of algal-derived materials, with some combinations associated with slower and less efficient virus spread in contact-exposed birds.

In addition to university-based research, ZIVO has disclosed collaborations and relationships with major global animal health companies. These arrangements include confirmatory studies funded by a collaborating company and agreements to evaluate ZIVO’s immune-enhancing compounds as biologics that may complement existing poultry vaccination strategies. The company has also discussed ongoing licensing dialogues and potential exclusive licensing arrangements for its coccidiosis product candidate with global animal health companies, subject to due diligence and definitive agreements.

Human nutrition and antioxidant-focused applications

Beyond animal health, ZIVO has communicated a focus on human nutrition. The company describes its algae platform as a source of natural antioxidant solutions. In one shareholder communication, ZIVO reported an independent biochemical analysis of its algae product conducted at the request of a prospective customer. According to that description, the algae contained substantial levels of antioxidants such as Superoxide Dismutase (SOD) and catalase, along with vitamins, carotenoids and proteins. The company also noted that, in a side-by-side comparison with another algae-based product, its algae showed higher SOD activity on average.

These findings are presented by ZIVO as supporting the potential use of its algae-derived materials as natural antioxidant ingredients in the nutraceutical marketplace. The company has indicated that it is in discussions with nutraceutical clients regarding commercial commitments for human health applications, although specific agreements are not detailed in the provided materials.

Research collaborations and development approach

ZIVO’s development strategy, as reflected in its public statements, relies heavily on:

• Controlled challenge studies in poultry, including 42-day grow-out studies for coccidiosis
• University collaborations, notably with the University of Delaware’s Department of Animal and Food Sciences
• Partnerships and funded studies with global animal health companies

These studies are used to evaluate endpoints such as intestinal lesion scores, feed conversion ratio, viral titers, and transmission dynamics in disease models. The company positions these data as the basis for potential regulatory submissions, including references to the USDA’s Center for Veterinary Biologics in the context of poultry biologics, and as support for commercial licensing discussions.

Corporate and regulatory context

ZIVO Bioscience, Inc. is incorporated in Nevada, as indicated in an 8-K filing. The company has traded under the symbol ZIVO, and its shares have been quoted on markets such as OTCQB and, in one news release, NASDAQ. The filings and news items provided do not indicate delisting, merger, bankruptcy or cessation of operations; instead, they describe ongoing R&D, collaborations and corporate activities.

The company’s SEC filings also document changes in financial leadership, including the resignation of a Chief Financial Officer and the appointment of an interim Chief Financial Officer under an independent contractor services agreement. These disclosures illustrate that ZIVO is subject to standard public company reporting requirements, including the need to report executive changes and related compensation arrangements.

Position within biological product manufacturing

Within the broader manufacturing sector, ZIVO aligns with biological product manufacturing focused on non-diagnostic applications. Its emphasis on proprietary algal and bacterial strains, biologically active molecules and complexes, and cultivation techniques places it at the intersection of biotechnology, agriculture and animal health. The company’s communications consistently frame its work as developing natural, non-antibiotic solutions intended for use in animal feed, biologics and nutritional products, with an emphasis on poultry health and antioxidant-rich algae for human nutrition.

Because ZIVO describes itself as a research and development company, its activities are centered on generating scientific data, advancing product candidates through studies and collaborations, and pursuing potential licensing or commercialization pathways with industry partners. Investors and observers evaluating ZIVO typically consider its pipeline of algal-derived compounds, the outcomes of its poultry and nutrition studies, and the progress of its relationships with animal health and nutraceutical companies, as reflected in the company’s own disclosures.